Anika Therapeutics (NASDAQ:ANIK) and Carmell (NASDAQ:CTCX) Head to Head Analysis

Carmell (NASDAQ:CTCX) and Anika Therapeutics (NASDAQ:ANIK) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, profitability, institutional ownership, earnings, valuation, risk and analyst recommendations.

Earnings and Valuation

This table compares Carmell and Anika Therapeutics”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Carmell	$12,320.00	727.94	-$15.44 million	N/A	N/A
Anika Therapeutics	$166.88 million	2.20	-$82.67 million	($5.25)	-4.80

Carmell has higher earnings, but lower revenue than Anika Therapeutics.

Risk and Volatility

Carmell has a beta of 0.34, indicating that its stock price is 66% less volatile than the S&P 500. Comparatively, Anika Therapeutics has a beta of 0.83, indicating that its stock price is 17% less volatile than the S&P 500.

Analyst Ratings

This is a summary of recent ratings for Carmell and Anika Therapeutics, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Carmell	0	0	0	0	N/A
Anika Therapeutics	0	1	1	0	2.50

Anika Therapeutics has a consensus price target of $30.50, indicating a potential upside of 21.03%. Given Anika Therapeutics’ higher probable upside, analysts clearly believe Anika Therapeutics is more favorable than Carmell.

Insider & Institutional Ownership

24.2% of Carmell shares are held by institutional investors. Comparatively, 91.5% of Anika Therapeutics shares are held by institutional investors. 29.0% of Carmell shares are held by company insiders. Comparatively, 7.9% of Anika Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Profitability

This table compares Carmell and Anika Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Carmell	N/A	-148.47%	-40.47%
Anika Therapeutics	-44.45%	0.94%	0.75%

Summary

Anika Therapeutics beats Carmell on 7 of the 11 factors compared between the two stocks.

About Carmell

Carmell Corporation operates as a bio-aesthetics company. The company utilizes Carmell Secretome to support skin and hair health. Its Carmell Secretome consists of growth factors and proteins extracted from allogeneic human platelets sourced from tissue banks. The company also developed a microemulsion formulation that enables delivery of lipophilic and hydrophilic ingredients without relying on the Foul Fourteen, 14 potentially harmful excipients that are commonly used by other companies to impart texture, stability, and other desirable physicochemical attributes to cosmetic products. In addition, the company is also developing a line of men's products and a line of topical haircare products. It has licensing agreement with Carnegie Mellon University to develop and commercialize biocompatible plasma-based plastics. The company was formerly known as Carmell Therapeutics Corporation and changed its name to Carmell Corporation in November 2023. Carmell Therapeutics Corporation was founded in 2008 and is headquartered in Pittsburgh, Pennsylvania.

About Anika Therapeutics

Anika Therapeutics, Inc., a joint preservation company, creates and delivers advancements in early intervention orthopedic care in the areas of osteoarthritis (OA) pain management, regenerative solutions, sports medicine, and arthrosurface joint solutions in the United States, Europe, and internationally. The company develops, manufactures, and commercializes products based on hyaluronic acid (HA) technology platform. Its OA pain management products includes Monovisc and Orthovisc, an injectable HA-based viscosupplement for the pain relief from osteoarthritis conditions; and Cingal, a single-injection OA pain management product to provide both short- and long-term pain relief. The company's joint preservation and restoration product family comprises and orthopedic regenerative solutions, including Hyalofast and Tactoset; sports medicine solutions used to repair and reconstruct damaged ligaments and tendons; and preserving joint solutions, including partial joint replacement, joint resurfacing, and invasive and bone sparing implants, which are designed to treat upper and lower extremity orthopedic conditions. In addition, it offers non-orthopedic products comprising HA-based products for non-orthopedic applications including Hyvisc, a molecular weight injectable HA veterinary product; Hyalobarrier, an anti-adhesion barrier indicated for use after abdominal-pelvic surgeries; and Hyalomatrix used for the treatment of burns and ulcers, as well as products used for the treatment of ears, nose and throat disorders, and ophthalmic products. The company was founded in 1983 and is headquartered in Bedford, Massachusetts.